Evidence map›Paper›PMID 42038342›Full record

ArticleDrug target insights

Molecular docking and dynamics analysis of selected phytocompounds against multi-targeted hepatocellular carcinoma.

Narendran Chiterasu, Swarnalatha Yanamandala, Senthilkumar Chinnaiyan, Sivakumar Shanthirappan, Sidhika Kannan, Paul X Clinton, Karthick Vadivel, Kiruthika Alepalli Rangan, Suresh Babu Yashwanth

Abstract read
In one paragraph

Article in Drug target insights. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Narendran ChiterasuCentre for Molecular and Nanomedical Science, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
Swarnalatha YanamandalaRajalakshmi Engineering College, Thandalam, Chennai (Tamil Nadu) - India.
Senthilkumar ChinnaiyanCentre for Molecular and Nanomedical Science, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
Sivakumar ShanthirappanDepartment of Gunapadam, National Institute of Siddha, Chennai (Tamil Nadu) - India.
Sidhika KannanCentre for Molecular and Nanomedical Science, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
Paul X ClintonCentre for Climate Change Studies, International Research Centre, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
Karthick VadivelCentre for Molecular and Nanomedical Science, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
Kiruthika Alepalli RanganDepartment of Biotechnology, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
Suresh Babu YashwanthDepartment of Biotechnology, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide, with a five-year survival rate of only 19%. Although Sorafenib is the primary systemic therapy, its limited efficacy and complex interactions with signaling pathways highlight the need for multi-target drugs. Methods: This study evaluates the anti-cancer properties of selected phytochemicals against six key HCC target proteins, utilizing sorafenib tosylate as a positive control. Molecular docking was performed to evaluate binding affinities and interactions, and ADME/T predictions were generated to estimate drug-like properties. The top-ranking candidates were further evaluated using 100-ns molecular dynamics simulations to analyze conformational stability, protein-ligand interactions, and residue mobility. Results: Silymarin (SA) emerged as the most effective compound, demonstrating greater predicted inhibitory activity than Sorafenib. SA showed high binding affinity for target proteins 6HH1 (-9.9 kcal/mol) and 1CM8 (-9.6 kcal/mol). Molecular dynamics simulations also revealed increased stability of the SA-protein complexes, particularly for the 1CM8-SA complex, which maintained high conformational stability. The root-mean-square deviation (RMSD) value was found to be around 2.1 Å, and the root-mean-square fluctuation (RMSF) values were below 3 Å, indicating lower protein flexibility compared to both the native and sorafenib-bound complexes. Conclusion: These computational findings provide a strong theoretical basis for Silymarin's efficacy as a highly potent, multi-targeted therapeutic agent against HCC. The improved stability and binding properties of Silymarin compared with Sorafenib provide a strong rationale for advancing this compound into preclinical and clinical studies.

Indexed as

Hepatocellular carcinomaMolecular dockingMolecular dynamicsPhytochemicalsToxicity

Identifiers

PMID42038342
PMCPMC13107123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.